Two independent Ludwig Cancer Research studies published in the March 30, 2023 issue of Cell show that immune cells known as neutrophils, whose abundance in the microenvironment of tumors has traditionally been associated with poor patient prognosis, can play an important role in the success of cancer immunotherapies. One study, co-led by Ludwig Lausanne Member Mikaël Pittet and Allon Klein of Harvard Medical School, identifies a functional state assumed by neutrophils following immunotherapy—termed the Sellhi state—in which they become formidable agents of antitumor immunity in mouse models of lung and colon cancer. This article is titled “A Neutrophil Response Linked to Tumor Control in Immunotherapy.”
Login Or Register To Read Full Story